Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Harkness
K A
KA
Manford
M R A
MR
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001763:Blepharoptosis / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D020226:Cavernous Sinus Thrombosis / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology*; D003391:Cranial Nerves / Q000473:pathology / Q000503:physiopathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017809:Fatal Outcome; D006261:Headache / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000532:radiotherapy / Q000556:secondary*; D009362:Neoplasm Metastasis / Q000473:pathology / Q000532:radiotherapy; D009886:Ophthalmoplegia / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D009918:Orbital Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000473:pathology*; D015996:Survival Rate; D000077204:Temozolomide
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003606:Dacarbazine; D000077204:Temozolomide